{"filing":{"accession_number":"0001193125-26-385901","cik":"0001782223","ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"pyxs-20260909.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526385901/pyxs-20260909.htm"},"events":[{"id":32190,"run_id":29572,"accession_number":"0001193125-26-385901","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Pyxis Oncology disclosed updated Phase 1 clinical trial data for its lead candidate MICVO in head and neck cancer, demonstrating efficacy results (36% cORR, 94% DCR, 6.2-month mPFS, 79% 12-month OS) and a manageable safety profile with no new safety signals. The company plans to initiate a Phase 3 pivotal trial in mid-2027 with FDA/EMA alignment on trial design, representing a material de-risking milestone for the company's lead program.","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35302,"accession_number":"0001193125-26-385901","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Pyxis Oncology disclosed updated Phase 1 clinical trial data for its lead candidate MICVO, including efficacy results (36% cORR, 94% DCR, 6.2-month mPFS, 79% 12-month OS) and safety findings, along with plans to initiate a Phase 3 pivotal trial in mid-2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the registrant's pipeline progress and commercial prospects, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other defined event types. The disclosure is operational in nature—a significant clinical advancement—rather than financial, governance, or legal.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:36:07.154181+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35303,"accession_number":"0001193125-26-385901","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive updated Phase 1 clinical trial data for MICVO in head and neck cancer, including efficacy metrics (36% cORR, 94% DCR, 6.2-month mPFS, 79% 12-month OS probability) and a manageable safety profile with no new safety signals. While clinical-stage biotech companies routinely report trial progress, this represents a material operational milestone—the data support advancement to a pivotal Phase 3 trial planned for mid-2027 and FDA/EMA alignment on trial design. This is a significant de-risking event for the company's lead program, affecting investor assessment of the registrant's prospects, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:36:07.154181+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35302,"accession_number":"0001193125-26-385901","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Pyxis Oncology disclosed updated Phase 1 clinical trial data for its lead candidate MICVO, including efficacy results (36% cORR, 94% DCR, 6.2-month mPFS, 79% 12-month OS) and safety findings, along with plans to initiate a Phase 3 pivotal trial in mid-2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the registrant's pipeline progress and commercial prospects, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other defined event types. The disclosure is operational in nature—a significant clinical advancement—rather than financial, governance, or legal.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:36:07.154181+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-09-09"},{"id":35303,"accession_number":"0001193125-26-385901","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive updated Phase 1 clinical trial data for MICVO in head and neck cancer, including efficacy metrics (36% cORR, 94% DCR, 6.2-month mPFS, 79% 12-month OS probability) and a manageable safety profile with no new safety signals. While clinical-stage biotech companies routinely report trial progress, this represents a material operational milestone—the data support advancement to a pivotal Phase 3 trial planned for mid-2027 and FDA/EMA alignment on trial design. This is a significant de-risking event for the company's lead program, affecting investor assessment of the registrant's prospects, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:36:07.154181+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-09-09"}]}